212 related articles for article (PubMed ID: 37627164)
1. In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia.
Boulos JC; Chatterjee M; Shan L; Efferth T
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627164
[TBL] [Abstract][Full Text] [Related]
2. Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma.
Boulos JC; Omer EA; Rigano D; Formisano C; Chatterjee M; Leich E; Klauck SM; Shan LT; Efferth T
Acta Pharmacol Sin; 2023 Nov; 44(11):2265-2281. PubMed ID: 37344563
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells.
Boulos JC; Saeed MEM; Chatterjee M; Bülbül Y; Crudo F; Marko D; Munder M; Klauck SM; Efferth T
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832908
[TBL] [Abstract][Full Text] [Related]
4. Adapalene suppressed the proliferation of melanoma cells by S-phase arrest and subsequent apoptosis via induction of DNA damage.
Li H; Wang C; Li L; Bu W; Zhang M; Wei J; Tao L; Qian K; Ma P
Eur J Pharmacol; 2019 May; 851():174-185. PubMed ID: 30836068
[TBL] [Abstract][Full Text] [Related]
5. The third-generation retinoid adapalene triggered DNA damage to induce S-phase arrest in HaCat cells.
Wang C; Li H; Ma P; Sun J; Li L; Wei J; Tao L; Qian K
Fundam Clin Pharmacol; 2020 Jun; 34(3):380-388. PubMed ID: 31808972
[TBL] [Abstract][Full Text] [Related]
6. The Novel Artemisinin Dimer Isoniazide ELI-XXIII-98-2 Induces c-MYC Inhibition, DNA Damage, and Autophagy in Leukemia Cells.
Elbadawi M; Boulos JC; Dawood M; Zhou M; Gul W; ElSohly MA; Klauck SM; Efferth T
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111592
[TBL] [Abstract][Full Text] [Related]
7. The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cells in vitro.
Ocker M; Herold C; Ganslmayer M; Hahn EG; Schuppan D
Int J Cancer; 2003 Nov; 107(3):453-9. PubMed ID: 14506747
[TBL] [Abstract][Full Text] [Related]
8. Targeting AR-positive breast cancer cells via drug repurposing approach.
Dutta P; Sen P; Kandasamy T; Ghosh SS
Comput Biol Chem; 2024 Feb; 108():108007. PubMed ID: 38157661
[TBL] [Abstract][Full Text] [Related]
9. Rational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents.
Manchukonda NK; Naik PK; Santoshi S; Lopus M; Joseph S; Sridhar B; Kantevari S
PLoS One; 2013; 8(10):e77970. PubMed ID: 24205049
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of N-acyl Derivatives of Aminocombretastatin A-4 and Study of their Interaction with Tubulin and Downregulation of c-Myc.
Agut R; Falomir E; Murga J; Martín-Beltrán C; Gil-Edo R; Pla A; Carda M; Díaz JF; Josa-Prado F; Marco JA
Med Chem; 2021; 17(10):1129-1139. PubMed ID: 33222678
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in receptor-selective retinoids.
Nagpal S; Chandraratna RA
Curr Pharm Des; 2000 Jun; 6(9):919-31. PubMed ID: 10828316
[TBL] [Abstract][Full Text] [Related]
12. Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1.
Wang Q; Zhang Q; Luan S; Yang K; Zheng M; Li K; Chen L; Li H
Bioorg Chem; 2019 Dec; 93():103315. PubMed ID: 31605927
[TBL] [Abstract][Full Text] [Related]
13. Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells.
Jinno H; Steiner MG; Nason-Burchenal K; Osborne MP; Telang NT
Int J Oncol; 2002 Jul; 21(1):127-34. PubMed ID: 12063559
[TBL] [Abstract][Full Text] [Related]
14. The role of specific retinoid receptors in sebocyte growth and differentiation in culture.
Kim MJ; Ciletti N; Michel S; Reichert U; Rosenfield RL
J Invest Dermatol; 2000 Feb; 114(2):349-53. PubMed ID: 10651997
[TBL] [Abstract][Full Text] [Related]
15. Modes of Action of a Novel c-MYC Inhibiting 1,2,4-Oxadiazole Derivative in Leukemia and Breast Cancer Cells.
Zhou M; Boulos JC; Omer EA; Klauck SM; Efferth T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570631
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma.
Yao R; Xie Y; Sun X; Zhang M; Zhou J; Liu L; Gao J; Xu K
Drug Des Devel Ther; 2020; 14():3983-3993. PubMed ID: 33061303
[TBL] [Abstract][Full Text] [Related]
17. Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells.
Saeed MEM; Boulos JC; Mücklich SB; Leich E; Chatterjee M; Klauck SM; Efferth T
Cancer Genomics Proteomics; 2022; 19(5):540-555. PubMed ID: 35985681
[TBL] [Abstract][Full Text] [Related]
18. Adapalene, a new chemical entity with retinoid activity.
Bernard BA
Skin Pharmacol; 1993; 6 Suppl 1():61-9. PubMed ID: 8142113
[TBL] [Abstract][Full Text] [Related]
19. Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.
Yao R; Zhang M; Zhou J; Liu L; Zhang Y; Gao J; Xu K
Cell Commun Signal; 2022 May; 20(1):73. PubMed ID: 35619182
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.
Yang J; Cao C; Luo D; Lan S; Luo M; Shan H; Ma X; Liu Y; Yu S; Zhong X; Li R
Eur J Med Chem; 2020 Jul; 198():112336. PubMed ID: 32387836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
